1. Lung Cancer Research Report Site Specific Group Meeting Tuesday 11th November Maxine Taylor Senior Research Delivery Manager

2. Content of report Overview of network changes
Overview of research activity
New studies for the portfolio
Request for research lead

3. Introduction
NIHR Clinical Research Network merged all cancer research networks with all other clinical research networks in England on 1st April 2014
CRN - West of England is one of 15 new networks
This new geography does not map exactly to the site specific group geography. It now includes Gloucestershire and Swindon but no longer includes Taunton and Yeovil
Taunton and Yeovil are served by the CRN – South West Peninsula
I will work closely with my counterpart in South West Peninsula to support this SSG in full

4. Map showing the 15 Clinical Research Networks in England
West of England
Population 2.4 million
- Budget £13.2 million
- 7 Acute Trusts
- 2 Mental Health Trusts
- CCL Principal Treatment Centre
- Full team only since August 1st
- Small core support team based at host in Bristol
Research will follow patient pathways regardless of network geography

5. Purpose of the network
Translation of national workstreams and objectives (generic and specialty specific) with strategic oversight of research activity within the geography of CRN - West of England in terms of:
Portfolio
Balance, new studies, feasibility, industry trials
Performance
Targets, support timely set up, support timely recruitment
People
Skill mix, workforce flexibility, resources, training

6. CRN - West of England Management Model
Divisions 2 & 6
Divisions 3 & 4
Division 5
Division 1
Maxine Taylor
Senior RDM Workforce Development
Martine Cross
Senior RDM RM&G and Industry Lead
Ruth Allen
RDM
Business Intelligence lead
Chantal Sunter
PCPIE and Comms Lead
Mary Perkins
Chief Operating Officer

7. Network Clinical Divisions
Cancer
Division 1
Diabetes Renal
Stroke Metabolic & endocrine
Cardiovascular
Division 2
Children Reproductive health & childbirth
Genetics Haematology
Division 3
Mental Health
Dementias & neurodegenerative diseases
Neurology
Division 4
Primary care Ageing Health services research
Oral & dental Dermatology
Musculoskeletal Public Health
Division 5
ENT Anaesthesia & pain management
Surgery Critical care
Respiratory Opthalmology
Critical care Infectious diseases
Hepatology Gastroenterology
Division 6

8. The Clinical Team Dr Steve Falk Clinical Director
6 Divisional Clinical Leads
Prof Hugh Barr for Div 1
30 Specialty Leads
Sub Specialty Leads
Sue Taylor
Network Consultant Nurse
Clinical Research Teams

9. Cancer specialty specific objectives
NIHR CRN High Level Objectives
Set up as fast as you can
Recruit as many and as fast as you can
All organisations involved
Commercial and non commercial portfolio studies
Cancer specialty specific objectives
Recruitment overall at 20% cancer incidence
Recruitment to interventional studies at 7.5% of cancer incidence

10. How important is cancer on our patch?
Cancer incidence 9544
242 recruiting studies
£2 million (16%)
Funding per incident case approx £220
Funding per recruit £800
Exceeded both recruitment targets for last 2 years
Largest non commercial portfolio
Benefit from continued good national and international links

11. West of England specialty portfolio compared to national
Total studies 3827
WE total 546
=14%

13. Recruitment by Trust and study design April – Oct 2014

14. Recruitment by Trust and study April – Oct 2014

15. WE Lung portfolio

16. New studies to discuss: Portfolio search criteria – open to new sites with >12 months to run
SPUtNIk - Accuracy and cost-effectiveness of dynamic contrast enhanced computed tomography in the characterisation of solitary pulmonary nodule
Closure date – March 2017
CI Dr Steve George, Southampton
TAPPS - Evaluating the efficacy of thoracoscopy and talc poudrage versus pleurodesis using talc slurry: a randomised trial to determine the most effective method for the management of malignant pleural effusions in patients with a good performance status
Closure date – Jan 2017
CI Dr Nick Maskell, NBT, Bristol
MARS2
A study to determine if it is feasible to recruit into a randomised trial comparing (extended) pleurectomy decortication versus no pleurectomy decortication in the multimodality management of patients with malignant pleural mesothelioma
IN SET UP. CI – Dr Eric Lim, Royal Brompton, London

17. New studies continued
CEDAR - A Phase II, randomised, open-label study of Gemcitabine/Carboplatin first-line chemotherapy in combination with or without the antisense oligonucleotide Apatorsen (OGX427) in advanced squamous cell lung cancers
Closure date – Dec 2016
CI – Prof Peter Schmid, Queen Mary’s, London

18. Commercial studies
NCRN569- LDK378 in ALK+ advanced NSCLC - ASCEND IV - A phase III multicenter, randomized study of oral LDK378 versus standard chemotherapy in previously untreated adult patients with ALK rearranged (ALK-positive), locally advanced or metastatic, non-squamous non-small cell lung cancer
NCRN552- ASCEND V - A phase III, multicenter, randomized, open-label study of oral LDK378 versus standard chemotherapy in adult patients with ALK-rearranged (ALK-positive) advanced non-small cell lung cancer who have been treated previously with chemotherapy (platinum doublet) and crizotinib
NCRN VESTA: Veliparib, carboplatin & paclitaxel in NSCLC - A Randomized, Double-Blind, Multicenter, Phase 3 Study Comparing Veliparib PlusCarboplatin and Paclitaxel Versus Placebo Plus Carboplatin and Paclitaxel in Previously UntreatedAdvanced or Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC)

19. Cancer Subspecialty Research Leads
Within each network 13 subspecialty research lead roles are identified, mapping onto the national Clinical Studies Groups with the aim of:
Providing link between local network and CSGs
Promoting the research agenda to clinical colleagues across the network
Advising on portfolio planning locally
Attendance at annual meeting to discuss portfolio planning and delivery and horizon scan for new studies
Supporting the research delivery manager for the cancer specialty
Role very similar to SSG Research Lead role

20. National Clinical Studies Groups PPI Psychosocial & Survivorship
Imaging Adv. panel
Breast Cancer
CSG
Brain Tumours
CSG
Lung Cancer
CSG
Palliative & Supportive
Care
Head & Neck
CSG
Biomarkers Adv. panel
Upper GI Cancer
CSG
Consumer Liaison Group
Sarcoma
CSG
PPI
Colorectal Cancer
CSG
Melanoma
CSG
Kidney Cancer
CSG
Primary
Care
Lymphoma
CSG
Bladder Cancer
CSG
Screening, Prevention & Early Diagnosis
Haematol.
CSG
Testis Cancer
CSG
Prostate Cancer
CSG
Gynae Cancer
CSG
Children’s Cancer & Leukaemia
Teenage &
Young Adult
CTRad (Radiotherapy)

21. LCRN (x15) CRN WE Exec Board COO Clinical Director
Partnership Group
Clin. Advisory Group
Clinical Director
COO
Division 1 Clinical Lead
Division 1 RDM
[ +/- other clinical roles]
13 LCRN Subspecialty Leads:
Brain cancer
H&N cancer
Lung cancer
Breast cancer
Sarcoma
Skin Cancer
Children/young people
Upper GI cancer
Colorectal cancer
Urological cancer
Gynae cancer
Haem/lymphoma
Pall/Supportive & Psychosocial
Research Delivery
Teams

22. Call for Lung sub-specialty lead in CRN - West of England
Each SSG already has a research lead
We are looking for a research lead in each tumour site to represent the network locally and nationally in terms of developing and supporting the portfolio and providing clinical specialty support to the Research Delivery Manager and Principal Investigators across the network
Expenses to attend national meetings will be met by the network
Please discuss:
Your current research lead continuing and taking on the network representation
The nomination of a new research lead who will take on network representation

23. Contact & reference details